X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs SUN PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA SUN PHARMA GSK PHARMA/
SUN PHARMA
 
P/E (TTM) x 65.0 25.7 252.6% View Chart
P/BV x 10.4 3.8 277.7% View Chart
Dividend Yield % 1.2 0.6 198.3%  

Financials

 GSK PHARMA   SUN PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
SUN PHARMA
Mar-17
GSK PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,838842 455.8%   
Low Rs2,637572 460.7%   
Sales per share (Unadj.) Rs354.2131.6 269.1%  
Earnings per share (Unadj.) Rs39.832.7 121.6%  
Cash flow per share (Unadj.) Rs42.938.0 112.9%  
Dividends per share (Unadj.) Rs30.003.50 857.1%  
Dividend yield (eoy) %0.90.5 187.2%  
Book value per share (Unadj.) Rs236.9152.7 155.2%  
Shares outstanding (eoy) m84.702,399.26 3.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.15.4 170.1%   
Avg P/E ratio x81.421.6 376.5%  
P/CF ratio (eoy) x75.518.6 405.5%  
Price / Book Value ratio x13.74.6 295.0%  
Dividend payout %75.410.7 704.9%   
Avg Mkt Cap Rs m274,2161,696,877 16.2%   
No. of employees `0004.717.5 26.8%   
Total wages/salary Rs m4,83049,023 9.9%   
Avg. sales/employee Rs Th6,387.018,028.3 35.4%   
Avg. wages/employee Rs Th1,028.32,798.8 36.7%   
Avg. net profit/employee Rs Th717.14,479.5 16.0%   
INCOME DATA
Net Sales Rs m30,000315,784 9.5%  
Other income Rs m7286,232 11.7%   
Total revenues Rs m30,728322,016 9.5%   
Gross profit Rs m4,190100,893 4.2%  
Depreciation Rs m26312,648 2.1%   
Interest Rs m03,998 0.0%   
Profit before tax Rs m4,65590,479 5.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,74412,116 14.4%   
Profit after tax Rs m3,36878,462 4.3%  
Gross profit margin %14.031.9 43.7%  
Effective tax rate %37.513.4 279.8%   
Net profit margin %11.224.8 45.2%  
BALANCE SHEET DATA
Current assets Rs m16,742329,537 5.1%   
Current liabilities Rs m7,202178,870 4.0%   
Net working cap to sales %31.847.7 66.7%  
Current ratio x2.31.8 126.2%  
Inventory Days Days5279 65.6%  
Debtors Days Days2183 25.0%  
Net fixed assets Rs m8,635204,766 4.2%   
Share capital Rs m8472,399 35.3%   
"Free" reserves Rs m19,222363,997 5.3%   
Net worth Rs m20,069366,397 5.5%   
Long term debt Rs m1014,361 0.1%   
Total assets Rs m30,038614,102 4.9%  
Interest coverage xNM23.6-  
Debt to equity ratio x00 1.3%  
Sales to assets ratio x1.00.5 194.2%   
Return on assets %11.213.4 83.5%  
Return on equity %16.821.4 78.4%  
Return on capital %25.524.8 102.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52844,118 1.2%   
Fx outflow Rs m7,19324,484 29.4%   
Net fx Rs m-6,66519,634 -33.9%   
CASH FLOW
From Operations Rs m2,36070,822 3.3%  
From Investments Rs m3,008-42,216 -7.1%  
From Financial Activity Rs m-5,108-22,854 22.3%  
Net Cashflow Rs m2606,107 4.3%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 5.1 198.8%  
FIIs % 23.8 23.0 103.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 8.3 185.5%  
Shareholders   102,036 133,026 76.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS